Phase II study of VNP40101M in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplasia (MDS)

F. Giles,S. OBrien,Norbert Vey,Eric J. Feldman,David A. Rizzieri,Khuda Khan,Syed Fazl Ali Bilgrami,Gregor Verhoef,Ghulam J. Mufti,Bonny Johnson,Judith E. Karp

Phase II study of VNP40101M in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplasia (MDS)

2005

F. Giles
S. OBrien
Norbert Vey
Eric J. Feldman
David A. Rizzieri
Khuda Khan
Syed Fazl Ali Bilgrami
Gregor Verhoef
Ghulam J. Mufti
Bonny Johnson
Judith E. Karp

6541 Background: VNP40101M is a novel sulfonylhydrazine alkylating agent with significant activity in refractory AML. In a phase I single agent study of pts with relapsed/refractory leukemias, the ...

Keywords:

Physical therapy
Cancer research
Acute myelogenous leukemia (AML)
Medicine
Pathology
Oncology
Phases of clinical research
in patient
single agent
Refractory
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations